News articles about CTI BioPharma (NASDAQ:CTIC) have been trending somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. CTI BioPharma earned a news impact score of 0.16 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.618567357303 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Several equities research analysts have weighed in on CTIC shares. ValuEngine downgraded CTI BioPharma from a “sell” rating to a “strong sell” rating in a report on Wednesday, October 11th. Zacks Investment Research raised CTI BioPharma from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a report on Wednesday, December 27th.
Shares of CTI BioPharma (NASDAQ:CTIC) opened at $3.41 on Friday. The company has a quick ratio of 2.17, a current ratio of 2.19 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $146.52, a PE ratio of -2.87 and a beta of 0.53. CTI BioPharma has a twelve month low of $2.45 and a twelve month high of $5.64.
CTI BioPharma (NASDAQ:CTIC) last issued its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.04. CTI BioPharma had a negative return on equity of 209.67% and a negative net margin of 96.91%. The business had revenue of $1.71 million during the quarter, compared to the consensus estimate of $0.30 million. sell-side analysts forecast that CTI BioPharma will post -1.2 EPS for the current year.
WARNING: “CTI BioPharma (CTIC) Getting Somewhat Favorable Media Coverage, Study Shows” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/01/14/cti-biopharma-ctic-getting-somewhat-favorable-media-coverage-study-shows.html.
CTI BioPharma Company Profile
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.